Oropharyngeal Cancer | Norton Healthcare

Indication: Oropharyngeal Cancer

NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Early-Stage, p16-Positive, Non-Smoking pts

Drug Study

Principal Investigator: Aaron Spalding, M.D.
Norton Cancer Institute

Sponsor: NRG Oncology

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.